Your browser doesn't support javascript.
loading
Experience with ceftazidime-avibactam treatment in a tertiary care center in Saudi Arabia.
Algwizani, Abdullah; Alzunitan, Mohammad; Alharbi, Ahmad; Alsaedy, Abdulrahman; Aljohani, Sameera; Alalwan, Bassam; Gramish, Jawaher; Alothman, Adel.
Afiliação
  • Algwizani A; Division of Infectious Diseases, Department of Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia; King Abdullah International Medical Research Center - King Saud bin Abdulaziz University - Health Sciences, Riyadh, Saudi Arabia.
  • Alzunitan M; Division of Infectious Diseases, Department of Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
  • Alharbi A; Division of Infectious Diseases, Department of Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
  • Alsaedy A; Division of Infectious Diseases, Department of Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia; College of Medicine, King Saud bin Abdulaziz University-Health Sciences, Riyadh, Saudi Arabia; King Abdullah International Medical Research Center - King Saud bin Abdulaziz University - Health
  • Aljohani S; College of Medicine, King Saud bin Abdulaziz University-Health Sciences, Riyadh, Saudi Arabia; Division of Microbiology, Department of Pathology, King Abdulaziz Medical City, Riyadh, Saudi Arabia; King Abdullah International Medical Research Center - King Saud bin Abdulaziz University - Health Scien
  • Alalwan B; Division of Microbiology, Department of Pathology, King Abdulaziz Medical City, Riyadh, Saudi Arabia; King Abdullah International Medical Research Center - King Saud bin Abdulaziz University - Health Sciences, Riyadh, Saudi Arabia.
  • Gramish J; Department of Pharmacy, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
  • Alothman A; Division of Infectious Diseases, Department of Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia; College of Medicine, King Saud bin Abdulaziz University-Health Sciences, Riyadh, Saudi Arabia; King Abdullah International Medical Research Center - King Saud bin Abdulaziz University - Health
J Infect Public Health ; 11(6): 793-795, 2018.
Article em En | MEDLINE | ID: mdl-29706317
ABSTRACT

INTRODUCTION:

Carbapenem-resistant organisms have become major healthcare-associated pathogens and are responsible for significant morbidity and mortality worldwide. CASES AND MANAGEMENTS This case-series describes our experience with ceftazidime-avibactam in the treatment of six cases with carbapenem-resistant organisms in King Abdulaziz Medical City in Riyadh, Saudi Arabia. After trying various combinations of antibiotic therapies without improvement, cases were treated with ceftazidime-avibactam.

OUTCOMES:

Five of the six achieved complete cure, both clinically and microbiologically.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ceftazidima / Infecções por Bactérias Gram-Negativas / Compostos Azabicíclicos / Inibidores de beta-Lactamases / Antibacterianos Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ceftazidima / Infecções por Bactérias Gram-Negativas / Compostos Azabicíclicos / Inibidores de beta-Lactamases / Antibacterianos Idioma: En Ano de publicação: 2018 Tipo de documento: Article